Abstract: Neurological disorders involving loss of neurons had been though incurable since the neurons are not regenerate in adults. Disclosed is a combination treatment of MS-818 and phenserine increased neurogenesis under AD pathological conditions. However, any brain damage, including stroke, Alzheimer's disease, ALS, MS, Parkinson's disease, traumatic brain injury, and even aging, is known to increase inflammatory signals (e.g., cytokines). We found those inflammatory signaling increased glial differentiation NSCs. Disclosed is a combination use of MS-818 and non-steroidal anti-inflammatory drug (NSAID) suppress inflammatory signaling increase neurogenesis, indicating this combination of the drugs could be useful as a therapy for any kind of neuronal damages.

Abstract: Methods and agents that target nanog or Oct4 expression or activity for treating or preventing cancer are disclosed. Alternative methods involve diagnosing cancer stage or type by identifying presence of cancer cells expressing nanog or Oct4. Also, disclosed are method of treating coronavirus infection that involves administering antiviral knockdown agents, such as oligonucleotide-based inhibitors.

Abstract: Disclosed herein are methods and materials for transdifferentiating mesenchymal stem cells into neural progenitor cells.

Abstract: Provided are methods of detecting cancer in a patient that involve analyzing DNA in extracellular vesicles. Detection may involve screening for an insert in a 3? UTR of NANOGP8 present in extracellular vesicles. A method involves (i) obtaining a biological sample containing extracellular vesicles from the patient; (ii) isolating the vesicles from the biological sample; (iii) detecting an amount of NANOG DNA in the vesicles; (iv) comparing the amount of NANOG DNA in the vesicles with vesicles in a non-cancer cell sample, wherein an increased level of NANOG DNA in the vesicles from the patient as compared to the non-cancer cell sample provides a positive indication of cancer in the patient.

Abstract: Disclosed herein are methods and materials for improving brain function and/or promoting neurogenesis in a patient suffering from impaired brain function. Specifically exemplified herein is the co-administration of phenserine and NBI-18.

Abstract: Disclosed herein are methods and materials for improving brain function and/or promoting neurogenesis m a patient suffering from impaired brain function. Specifically exemplified herein ls the co-administration of phenserine and NBI-18. A method of treating a neurodegenerative disease in a patient in need thereof, said method comprising co-administering to the patient phenserine, or pharmaceutically acceptable salt thereof, and NBI-18, or pharmaceutically acceptable salt thereof, in respective amounts and frequency such that they work together to improve brain function or induce neurogenesis in the patient.

Abstract: Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to enhance and/or improve the outcome of other therapies, and may be used in psychiatric applications. Increasing vigor in subjects is not necessarily targeted to the treatment of a disease, thus, the methods can include administration to clinically healthy animals.

Abstract: Disclosed herein are methods of detecting cancer in a patient that involve analyzing DNA in extracellular vesicles. In an exemplary embodiment, detection involves screening for an insert in a 3? UTR of NANOGP8.

Abstract: Disclosed herein are methods and materials for improving brain function and/or promoting neurogenesis m a patient suffering from impaired brain function. Specifically exemplified herein ls the co-administration of phenserine and NBI-18. A method of treating a neurodegenerative disease in a patient in need thereof, said method comprising co-administering to the patient phenserine, or pharmaceutically acceptable salt thereof, and NBI-18, or pharmaceutically acceptable salt thereof, in respective amounts and frequency such that they work together to improve brain function or induce neurogenesis in the patient.

Abstract: Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to enhance and/or improve the outcome of other therapies, and may be used in psychiatric applications. Increasing vigor in subjects is not necessarily targeted to the treatment of a disease, thus, the methods can include administration to clinically healthy animals.

Abstract: Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to enhance and/or improve the outcome of other therapies, and may be used in psychiatric applications. Increasing vigor in subjects is not necessarily targeted to the treatment of a disease, thus, the methods can include administration to clinically healthy animals.

Abstract: Systems and methods for camera-based fingertip tracking are disclosed. One such method includes identifying at least one location of a fingertip in at least one of the video frames, and mapping the location to a user input based on the location of the fingertip relative to a virtual user input device.

Abstract: Systems and methods for camera-based fingertip tracking are disclosed. One such method includes identifying at least one location of a fingertip in at least one of the video frames, and mapping the location to a user input based on the location of the fingertip relative to a virtual user input device.

Abstract: Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent cell capable of differentiating to a less developmentally potent cell of its lineage of origin or a different lineage.

Abstract: Disclosed herein are small-gap fullerene compositions and methods of using for therapeutic or cosmetic purposes. Specifically exemplified is the use of derivatized SGFs so as to be water-soluble. The derivatized SGFs include polyhydroxylated and polycarboxylated SGFs.

Abstract: This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells.

Abstract: Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells or mesenchymal stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.

Abstract: Systems and methods for camera-based fingertip tracking are disclosed. One such method includes identifying at least one location of a fingertip in at least one of the video frames, and mapping the location to a user input based on the location of the fingertip relative to a virtual user input device.

Abstract: The present invention is directed to methods and systems directed to altering the differentiation of a cell, more particularly to biasing a potent cell, such as a mesenchymal stem cell, by contacting such cell with a protein having properties of bone morphogenic protein-4. The contacting may be achieved via genetic modification, and the resulting cell may be or have characteristics of a pre-adipocyte. Pre-adipocyte cells so-obtained, and their progeny, may be used for various purposes, including in cosmetic and other surgical therapies and treatments.

Abstract: Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.